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Abstract
Background: The etiology of multiple sclerosis (MS) is at present not fully elucidated, although it
is considered to result from the interaction of environmental and genetic susceptibility factors. In
this work we aimed at testing the Early B-cell Factor (EBF1) gene as a functional and positional
candidate risk factor for this neurological disease. Axonal damage is a hallmark for multiple sclerosis
clinical disability and EBF plays an evolutionarily conserved role in the expression of proteins
essential for axonal pathfinding. Failure of B-cell differentiation was found in EBF-deficient mice and
involvement of B-lymphocytes in MS has been suggested from their presence in cerebrospinal fluid
and lesions of patients.
Methods: The role of the EBF1 gene in multiple sclerosis susceptibility was analyzed by performing
a case-control study with 356 multiple sclerosis patients and 540 ethnically matched controls
comparing the EBF1 polymorphism rs1368297 and the microsatellite D5S2038.
Results: Significant association of an EBF1-intronic polymorphism (rs1368297, A vs. T: p = 0.02;
OR = 1.26 and AA vs. [TA+TT]: p = 0.02; OR = 1.39) was discovered. This association was even
stronger after stratification for the well-established risk factor of multiple sclerosis in the Major
Histocompatibility Complex, DRB1*1501 (AA vs. [TA+TT]: p = 0.005; OR = 1.78). A trend for
association in the case-control study of another EBF1 marker, the allele 5 of the very informative
microsatellite D5S2038, was corroborated by Transmission Disequilibrium Test of 53 trios (p =
0.03).
Conclusion: Our data support EBF1 gene association with MS pathogenesis in the Spanish white
population. Two genetic markers within the EBF1 gene have been found associated with this
neurological disease, indicative either of their causative role or that of some other polymorphism
in linkage disequilibrium with them.
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Multiple sclerosis (MS) is one of the most common neu-
rological diseases of young adults in Europe and North
America [1]. Similarly to other common complex dis-
eases, the interplay of genome and environment as MS
susceptibility factors seems to determine the final out-
come. Its precise etiology is at present unknown, even
though the first genetic association with the MHC was
published more than thirty years ago [2]. Genomic
screens support the hypothesis that susceptibility to
develop MS is determined by multiple genes with small
individual contributions. To decipher those combinations
of genes resulting in MS is a major goal of research. Asso-
ciation of MS with the HLA-DRB1*1501-DQB1*0602
haplotype has been unambiguously demonstrated [3].
The diversity of the predisposition genes is evident if we
consider that the major risk allele HLA-DRB1*1501 is
present only in 33% of our Spanish MS patients. New sus-
ceptibility genes are therefore actively sought worldwide.
In the past, candidate gene approaches have successfully
revealed associations with disease susceptibility, severity
or disease course.
MS has been traditionally considered an autoimmune
demyelinating disorder of the central nervous system
(CNS) due to autoreactive T cells on myelin proteins.
However, other cells and processes have also been
involved in the MS immune attack. A role for B cells in MS
pathogenesis has been suggested from their presence in
the cerebrospinal fluid and lesions of MS patients [4,5].
Axonal degeneration [6] has been found in early stages of
the disease [7]. Axonal loss is a reliable marker of MS clin-
ical disability [8], although the mechanism underlying
axonal damage in MS remains elusive [9,10].
B cells derive from a common lymphoid progenitor, itself
derived from a multipotent bone marrow progenitor. The
development of a B lymphocyte comprises multiple stages
with sequential expression of genes participating in
immunoglobulin gene rearrangements and signaling. B
cell development depends on a number of transcription
factors [11] including early B cell factor (EBF), as shown
for the dramatic phenotype of EBF-deficient mice [12]. B
cell differentiation to plasma cell in secondary lymphoid
organs is an exquisitely regulated process requiring EBF
inhibition [13] and a full recapitulation of this B cell final
differentiation has been recently described in the CSF
[14].
EBF [15] belongs to a family of proteins present in the ani-
mal kingdom, the Collier/Olf1/EBF proteins, and it is also
expressed in neural cells of different origins. EBF plays an
evolutionarily conserved role in the expression of proteins
essential for axonal pathfinding and neuronal differentia-
tion in both sensory and motor neurons [16]. In addition
to the action of the EBF protein in embryonic neural
development, it is expressed in the adult nervous system
too [17]. Furthermore, EBF binding activates the Herpes
Simplex Virus Type I ICP0 (Infected Cell Protein 0) gene
promoter, important for productive infection and reacti-
vation from latency [18]. This virus has been related to MS
[19,20].
All this evidence prompted us to determine whether the
EBF1 gene (coding for the first member of this family
cloned in humans), located at chromosome 5q has any
role in MS pathogenesis. Unfortunately, no description of
functional EBF1 polymorphisms exists in the literature,
and therefore two markers were selected based on strictly
genetic parameters. The first is the highly polymorphic
D5S2038 microsatellite mapping to the EBF1 gene and
the second an intronic single nucleotide polymorphism
(rs1368297). The present work shows association of these
markers with MS in the Spanish cohorts tested. Most
probably MS is consequence of the interaction of a limited
number of genetic and environmental risk factors in a




Three hundred and fifty six consecutively recruited MS
patients from a single center and 540 healthy controls,
mainly blood donors and staff, were included in a case-
control study approved by the Hospital Ethical commit-
tee. The MS diagnosis was established based on the Poser
criteria [21] and most of these patients have been
described in previous studies from our group [22].
Genotyping
D5S2038 microsatellite was amplified with annealing
temperature of 56°C using the following set of primers:
Forward: 5' FAM-GTT CAA ATC TTG CCT TTG CC-3'
Reverse: 5'-GCC ATT GCT TTG TTT ATG CA-3'
Samples were subsequently denatured and run on an ABI
Prism 3100 automatic sequencer (Applied Biosystems,
Foster City, CA, USA). Each sample included an internal
size standard in order to achieve a highly consistent meas-
ure and the results were analyzed using the GeneScan soft-
ware (Applied Biosystems) and the Local Southern
method.
The EBF1 polymorphism (rs1368297) was analyzed by
TaqMan Assays-on-Demand (C___2085085_10) from
Applied Biosystems, following manufacturer suggestions.Page 2 of 6
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librium in the control population.
Statistical analysis
Allele and genotype frequencies in patients and controls
were compared by the χ2 test; p values were considered
significant at a level of < 0.05. Odds ratio (OR) and p val-
ues were calculated using a standard computer package
(Epi Info v. 6.02, CDC, Atlanta, USA). The power of the
study for the SNP analyzed is above 80% considering a
relative risk of 1.4 and the observed allelic frequency of
0.5 at the standard significance level of 0.05.
Results
As microsatellites are very polymorphic and informative
genetic markers, we decided to select one within the EBF1
gene, D5S2038, and to study its allele distribution in our
cohorts. The case-control analysis of this microsatellite in
356 MS patients and 540 healthy controls yielded the
results summarized in Table 1. As shown, the only allele
displaying a trend for association was D5S2038*5, while
the frequency of the other ten alleles did not change sig-
nificantly when patients and controls were compared. No
differences were observed when different clinical forms
were compared (primary progressive vs relapsing-remit-
ting/secondary progressive). Considering these case-con-
trol results, we performed a Transmission Disequilibrium
Test (TDT) with 53 trios formed by the patients and their
progenitors. Distorted transmission of the D5S2038*5
was observed too (Table 2).
We pursued to check another polymorphism within the
EBF1 gene in order to provide more evidence in support
of the association of the gene with MS. Data correspond-
ing to the allele and genotype frequencies of the intronic
SNP rs1368297 are found in Table 3. Allele A was signifi-
cantly increased in the diseased population and, under a
recessive inheritance model, the AA homozygous geno-
type also conferred predisposition to MS. Moreover, the
ratio of risk: non-risk homozygous genotypes was signifi-
cantly higher among multiple sclerosis patients (AA: TT: p
= 0.03; OR [95%CI] = 1.56 [1.03–2.37]).
The MS cohort was stratified for the well-known MHC
susceptibility factor DRB1*1501 and the difference
between DRB1*1501+ patients and healthy controls was
even stronger than in the unconditioned analysis (Table
4).
Finally, when simultaneous carriage of both susceptibility
alleles, D5S2038*5 and EBF SNP*A, was compared
between MS patients and controls an increment was
observed within the diseased cohort (p = 0.03; OR
[95%CI] = 1.38 [1.03–1.84]).
Discussion
Information from genomic screens proposed the 5q chro-
mosomal region as linked to MS [23,24]. Additionally, a
recent report compared chromosomal regions, quantita-
tive trait loci (QTLs), of MS patients and of EAE animal
models and, by analysis of sequence similarities, defined
consensus genes potentially conferring susceptibility to
MS [25]. Among them, the EBF1 gene in chromosome
5q34 was cited, providing positional evidence of the role
of this gene in MS predisposition.
Moreover, the simultaneous measurement of thousands
of genes upregulated by EBF through microarray technol-
ogy allowed the detection of 3.5-fold increase in the
expression of interleukin 6 (IL-6) and of the microtubule
associated protein tau listed among the top twelve most
abundant transcripts [26]. IL-6 has been detected in MS
brain and its expression elevated in cerebrospinal fluid of
patients [27,28]. IL-6 knockout mice showed resistance to
induced EAE, too [29]. The physiological function of tau
is to bind to and stabilize microtubules [30] and it is
involved in regulation of axonal transport [31]. Tau pro-
tein concentration has been found repeatedly increased in
cerebrospinal fluid of MS patients [32]. Also morphologi-
cal examination demonstrated accumulation of amor-
Table 2: Transmission Disequilibrium Test (TDT) of EBF1 
microsatellite D5S2038 in trios (MS patient and progenitors).
EBF1 D5S2038 Transmitted Non transmitted p
3 5 9 0.91
4 23 11 0.44
5 28 15 0.03
6 3 8 0.96
7 3 7 0.94
8 11 10 0.50
9 0 2 1.00
10 1 1 0.75
Table 1: Allele frequencies of EBF1 microsatellite D5S2038 in MS 
patients and healthy controls.
EBF1 D5S2038 Controls (n = 540) MS patients (n = 356) p
1 2 2 0.99
2 27 15 0.58
3 55 36 0.97
4 272 176 0.78
5* 246 183 0.08
6 119 81 0.80
7 79 47 0.54
8 146 94 0.83
9 8 7 0.57
10 7 4 1.00
11 3 0 0.28
* p = 0.08; OR (95%CI) = 1.26 (0.96–1.67)Page 3 of 6
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cell body and axons of neurons within demyelinating
plaques in EAE [33]. Axonopathy has been involved
recently in early stages of the pathogenesis of another neu-
rological disease, Alzheimer's disease [34]. Aberrant accu-
mulation of proteins may be crucial to the impairment of
axonal transport.
Our results evidence association of the EBF1 gene with
MS. There are no functional studies of these gene poly-
morphisms, although it was cloned more than a decade
ago. However, several reports showed transcriptional reg-
ulatory elements located in intronic regions of different
genes [35-38]. In fact, the susceptibility allele of this EBF-
intronic polymorphism allows the putative binding of an
AP-1 transcription factor and this binding site is disrupted
in the presence of the T allele (as predicted by TFSEARCH
ver 1.3). Functional studies of EBF1 will aid in clarifying
the role of this gene in MS pathogenesis. Nonetheless, the
polymorphisms studied in this work act as genetic mark-
ers, which could potentially be the etiologic variants or be
in linkage disequilibrium with them.
The EBF prototypical regulatory activity in B lymphocyte
differentiation alone justifies the functional involvement
of the EBF1 gene in an autoimmune disease as MS.
Increasing evidence supports the role in MS disease course
of IgM antibodies [39] produced by CD5+ B-lymphocytes,
that are elevated in CSF of patients with aggressive forms
of MS [40]. These natural IgM antibodies recognize mye-
lin antigens and are strong complement activators [41].
Both, antibodies and complement, have been shown to
contribute to MS disability through demyelination and
axonal damage [42]. IgG antibodies with hypermutated V
regions have been also described [43]. Moreover, EBF1 is
a potent modulator of adipogenesis [44] and the IgM
bands in cerebrospinal fluid of MS patients were directed
against myelin lipids [40].
Conclusion
Our data suggest that the EBF1 gene involved in B-cell
development, adipogenesis and axonal damage play a
causative role in MS. Many mechanistic ties between
axonal damage, tau pathology, intrathecal B1 subpopula-
tion responsible for IgM secretion, conventional B cells,
and the EBF1 gene role in MS susceptibility could be
thought up. Confirmation in an independent cohort
would substantiate our hypothesis about the implications
of this gene in MS. Further understanding of the MS
pathogenesis will help in the selection of therapeutic tar-
gets and characterization of the specific susceptibility
genetic pattern in an individual will aid in a better diagno-
sis and ultimately in achievement of a personalized ther-
apy.
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Table 4: Genotype frequencies of the EBF1 polymorphism in 
HLA-DRB1*1501 positive and negative multiple sclerosis 
patients.
EBF rs1368297 AA AT TT A T
DRB1*1501+ MS patients* 51 53 19 155 91
(n = 123) 41.5% 43.1% 15.4% 63% 37%
DRB1*1501- MS patients 74 115 39 263 193
(n = 228) 32.5% 50.4% 17.1% 57.7% 42.3%
Controls 149 267 108 565 483
(n = 524) 28.4% 50.9% 20.6% 53.9% 46.1%
* AA vs. (AT+TT): p = 0.005; OR (95% CI) = 1.78 (1.16–2.73)
A vs. T: p = 0.01; OR (95% CI) = 1.46 (1.08–1.96)
Table 3: Allele and genotype frequencies of the EBF1 
polymorphism in multiple sclerosis patients and controls.
EBF rs1368297 AA AT TT A T
MS patients 125 168 58 418 284
(n = 351) 35.6% 47.8% 16.5% 59.5% 40.5%
Controls 149 267 108 565 483
(n = 524) 28.4% 50.9% 20.6% 53.9% 46.1%
AA vs. (AT+TT): p = 0.02; OR (95% CI) = 1.39 (1.03–1.88).
A vs. T: p = 0.02; OR (95% CI) = 1.26 (1.03–1.53).Page 4 of 6
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